BioImagene, Inc. was a prominent innovator in the field of digital pathology, providing comprehensive solutions including image analysis software, high-speed scanners for digitizing tissue slides, and workflow management systems. Founded in 1999, the company focused on transforming traditional pathology by enabling pathologists to view, manage, share, and analyze high-resolution digital images of tissue samples. This technology aimed to improve diagnostic accuracy, efficiency, and collaboration in cancer research and clinical settings. BioImagene was acquired by Roche in August 2010 for approximately $100 million, significantly enhancing Roche's portfolio in tissue-based diagnostics and contributing to the advancement of personalized healthcare.
The Sunnyvale headquarters served as the core for BioImagene's research and development, software engineering, corporate strategy, marketing, and administrative operations for its digital pathology solutions.
As a cutting-edge technology firm, the facility likely included specialized R&D labs for developing imaging hardware and pathology software, alongside modern office spaces designed to foster collaboration and innovation.
The work culture at BioImagene was likely dynamic and innovative, characteristic of a Silicon Valley tech company in the competitive medical technology sector. It would have emphasized scientific rigor, engineering excellence, and a fast-paced environment focused on disrupting traditional pathology practices.
This headquarters was crucial as the innovation hub where BioImagene developed its pioneering digital pathology technologies, contributing significantly to the early advancements in digitizing tissue diagnostics globally.
Before being acquired by Roche, BioImagene had established a growing global presence. Its operations were anchored by its headquarters in California and a major R&D and software development center in Pune, India. The company actively marketed and supported its digital pathology systems to laboratories, hospitals, and research institutions in North America, Europe, and parts of Asia, aiming to revolutionize pathology workflows worldwide.
760 N. Mary Ave
Sunnyvale
CA
USA
Address: Plot No. 20, Rajiv Gandhi Infotech Park, Phase-I, MIDC, Hinjewadi, Pune 411057, India (representative address)
This office played a key role in cost-effective product development and provided a base for potential expansion into Asian markets, supporting global operations with its technical expertise.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, BioImagene' leadership includes:
BioImagene has been backed by several prominent investors over the years, including:
BioImagene was acquired by Roche in August 2010. Consequently, there have been no executive new hires or exits for BioImagene as an independent entity in the last 12 months or any recent period. Leadership changes occurred at the time of and subsequent to the acquisition as part of its integration into Roche.
Discover the tools BioImagene uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Prior to its acquisition by Roche, BioImagene likely used standard corporate email formats for its employees. While not definitively documented publicly now, common formats included [first_initial][last]@bioimagene.com or [first].[last]@bioimagene.com. The domain 'bioimagene.com' now redirects to Roche.
[first_initial][last]@bioimagene.com (e.g., jdoe@bioimagene.com) or [first].[last]@bioimagene.com (e.g., jane.doe@bioimagene.com)
Format
jsmith@bioimagene.com
Example
0 (The bioimagene.com domain is no longer independently active for email)%
Success rate
Roche News Centre • August 24, 2010
Roche announced its acquisition of BioImagene, Inc., a privately-held company based in Cupertino, California, for approximately $100 million. BioImagene was recognized as a leader in digital pathology, offering innovative image analysis solutions critical for cancer diagnostics....more
PR Newswire • March 16, 2009
BioImagene announced the completion of a $15 million Series C financing round. The funding, led by existing investors like Nexus Venture Partners and new participation from CLSA Capital Partners, was aimed at accelerating the company's growth and market adoption of its digital pathology solutions....more
FierceBiotech • July 14, 2008
BioImagene entered into a strategic partnership with Agilent Technologies to co-market digital pathology solutions. This collaboration aimed to combine BioImagene's imaging systems with Agilent's reagents for pathology labs, enhancing research and diagnostic capabilities....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including BioImagene, are just a search away.